benralizumab

Ligand id: 7674

Name: benralizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: benralizumab

References
1. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al.. (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Lancet Respir Med, 2 (11): 879-90. [PMID:25306557]
2. Drugs.com. 
FDA Approves Fasenra.
Accessed on 16/11/2017. Modified on 16/11/2017. drugs.com, https://www.drugs.com/newdrugs/fda-approves-fasenra-benralizumab-severe-eosinophilic-asthma-4633.html?utm_source=ddc&utm_medium=email&utm_campaign=FDA+Approves+Fasenra+%28benralizumab%29+for+Severe+Eosinophilic+Asthma
3. European Medicines Agency. 
Fasenra.
Accessed on 16/11/2017. Modified on 16/11/2017. ema.europa.eu, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004433/smops/Positive/human_smop_001219.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human
4. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al.. (2016)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet, 388 (10056): 2128-2141. [PMID:27609406]
5. Ghazi A, Trikha A, Calhoun WJ. (2012)
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Expert Opin Biol Ther, 12 (1): 113-8. [PMID:22136436]
6. Koike M, Spitalny GL, Wheeler A, White B. (2013)
Methods of reducing eosinophil levels.
Patent number: US8501176. Assignee: Medimmune, Llc, Biowa, Inc.. Priority date: 14/05/2007. Publication date: 06/08/2013.
7. Mukherjee M, Sehmi R, Nair P. (2014)
Anti-IL5 therapy for asthma and beyond.
World Allergy Organ J, 7 (1): 32. [PMID:25709744]